Drug firm Sanofi India Ltd on Tuesday (April 28) reported a 14% decline in first-quarter net profit at ₹102.6 crore compared with ₹119.5 crore in the year-ago period. Revenue for the quarter fell 4.9% to ₹472.3 crore from ₹535.9 crore in the corresponding period last year.
EBITDA dropped 16.9% to ₹142.8 crore in Q1, compared with ₹171.9 crore a year earlier. The EBITDA margin stood at 30.2% versus 32.1% in the same quarter last year.
Sanofi India Ltd stated that in the domestic market, its insulin portfolio delivered strong performance for the second consecutive quarter, with double-digit growth on both a year-on-year basis and sequentially, reflecting its position in the diabetes injectable segment.
ALSO READ | Sanofi India shares fall 4% after company posts third straight quarter of revenue decline
The company said its strategic partnerships in cardiovascular (CV), oral anti-diabetes (OAD) and central nervous system (CNS) segments have created a stable base for operations. It added that overall quarterly results were impacted by transactions linked to partnership transitions.
Sanofi India also noted that export sales are stabilising despite geopolitical conditions. The company said it continues to pursue efficiency improvements through targeted market initiatives, refined go-to-market strategies and operational excellence programmes.
Deepak Arora, Managing Director, said, “Despite current focus on newer diabetes therapies, our 14% registered growth (vs the previous quarter) and 19% registered growth (vs last year) validate what clinical guidelines consistently affirm: insulin remains essential for comprehensive diabetes care.”
ALSO READ | Sanofi India Q3 Results: Profit and revenue decline, declares ₹75 interim dividend
“Our success across both public and private sectors reflects the medical community’s continued trust in insulin as the gold standard for reliable, predictable diabetes management — a position that remains unshakeable regardless of market trends. Our strategic partnerships will catalyse growth, strengthen our commercial footprint, enhance market penetration, and create meaningful connections with healthcare professionals across therapeutic areas.”
Shares of Sanofi India Ltd ended at ₹3,469, up by ₹35.95, or 1.05%, on the BSE today, April 28.
ALSO READ | Sanofi India Q4: Declares final dividend of ₹48; PAT surges 50%, revenue up 47%
First Published: Apr 28, 2026 7:22 PM IS
